Continue to deepen the reform of drug review and approval system and greet the successful holding of the 20 th National Congress of CPC with outstanding achievementsKONG Fan-pu1761-1766
Study on the"patent dance"system in the United States and its implication for ChinaWANG Xiu, LI Jia-ming, YAO Xue-fang, DING Jin-xi1767-1773
A case study of comprehensive efficacy evaluation of traditional Chinese medicines based on partial least squares second-order latent variable modelZHAO Yang, SUN Ming-yue, GAO Hong-yang, ZHANG Wan-tong, PU Xin-yi, YANG Xiao-chen, YI Dan-hui, GAO Rui1774-1778
Bylvay, a new drug for the treatment of progressive familial intrahepatic cholestasisLI Yan, LIU Xiao-yan, HE Xin1779-1783
Analysis of risk factors of monoclonal antibody drugs and general considerations of non-clinical research and evaluationDAI Xue-dong, WANG Yin, ZHOU Heng, YIN Hua-jing, FU Shu-jun, YIN Mao-shan, WU Shuang, YU Bing, SUN Tao, WANG Qing-li1784-1792
The development history and current implementation status of drug registration administrative acceptance in ChinaDONG Min, WU Zhi-ang, CUI Jing1793-1800
Considerations for designing observational studies using targeted trial emulation conceptZHAO Jun, WANG Jun1801-1803
Problems faced in the operation of clinical trials for diseases involving fever during the regular COVID-19 prevention and control period and countermeasuresCHENG Jin-lian, ZHU Xue-qi, LIU Lin, XIAO Shuang, WANG Shuo, WANG Yan, LIU Qing-quan1804-1809
Risk assessment of β-lactamase gene in mammalian cell expression systemLI Jing, WEI Su-zhen, HE Hua, CHEN Zong-meng, WU Qiang, ZHANG Xue-ying, LAI Yong-jie1810-1814
The progresses of clinical trials of roxadustat in the treatment of renal anemiaSHEN Fang-li, SONG Cang-sang, LI Xing-de, ZHANG Yang, LIU Lu, ZHANG Han-shu1815-1822